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ABSTRACT
Objective: The aim of this study was to examine the clinimetric properties of the AMC Linear
Disability Score (ALDS), a new generic disability measure based on Item Response Theory, in
patients with newly diagnosed Parkinson disease (PD).
Methods: A sample of 132 patients with PD was evaluated using the Hoehn and Yahr (H&Y), the
Unified PD Rating Scale motor examination, the Schwab and England scale (S&E), the Short
Form–36, the PD Quality of Life Questionnaire, and the ALDS.
Results: The internal consistency reliability of the ALDS was good (  0.95) with 55 items ex-
tending the sufficient item-total correlation criterion (r  0.20). The ALDS was correlated with
other disability measures (r  0.50 to 0.63) and decreasingly associated with measures reflect-
ing impairments (r  0.36 to 0.37) and mental health (r  0.23 to 0.01). With regard to know-
group validity, the ALDS indicated that patients with more severe PD (H&Y stage 3) were more
disabled than patients with mild (H&Y stage 1) or moderate PD (H&Y stage 2) (p  0.0001). The
ALDS discriminated between more or less severe extrapyramidal symptoms (p  0.001) and
patients with postural instability showed lower ALDS scores compared to patients without pos-
tural instability (p   0.0001). Compared to the S&E (score 100%  19%), the ALDS showed
less of a ceiling effect (5%).
Conclusion: The AMC Linear Disability Score is a flexible, feasible, and clinimetrically promising
instrument to assess the level of disability in patients with newly diagnosed Parkinson disease.
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GLOSSARY
ADL activities of daily living;ALDS AMC Linear Disability Score;ANOVA analysis of variance;H&YHoehn and Yahr;
IRT item response theory; PD Parkinson disease; PDQL PD Quality of Life Questionnaire; S&E Schwab and England
scale; SF Short Form; UPDRS Unified PD Rating Scale.
The impact of a disease on a patient’s level of activities of daily living (ADL) is generally
considered as an important outcome measure in clinical studies.1 This is not different in
patients with Parkinson disease (PD).2,3 Frequently used (disease-specific) disability
scales, such as the ADL part of the Unified PD Rating Scale (UPDRS-ADL),4 are
sumscore-based. Consequently, all items have to be presented to all patients irrespective
of their level of disability, which means that able patients as well as more disabled pa-
tients will be presented the same items, which may lead to ceiling and floor effects.5-7
Another disadvantage is that each scale contains different items, response options, and
scoring rules, which hinder direct comparisons of interventions.8 An alternative ap-
proach is the use of ordinal indexes, such as the Schwab & England Activities of Daily
Living Scale (S&E),9 which are less sensitive for subtle changes in a patient’s condition.
Currently, interest is moving toward the more flexible framework offered by item
response theory (IRT). An item bank is a collection of items for which the measurement
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properties of each item are known.10-12
Since IRT centers on the measurement
properties of individual items, rather than
the instrument as a whole, it is not essential
for all respondents to be examined using all
items when using an item bank. It is possi-
ble to select items for individual patients
using small sets of items tailored to the dis-
ability level of the patients.13 This can re-
duce the burden of testing considerably for
both patients and researchers. Examples of
other disability item banks are developed
by Haley et al.14 and Ware et al.15
Using modern clinimetric methods
based on IRT11 we developed a linear out-
come scale which can be used in both
mildly and severely affected patients.8,16,17
The AMC Linear Disability Score (ALDS)
is a generic, non-disease-specific item bank
consisting of 77 ADL items hierarchically
ordered from simple to complex. By using
a small number of items, tailored to the
ADL level of patients, a sufficiently de-
tailed clinical picture can be obtained.
Even if different sets of items are used for
different groups of patients, ALDS scores
can still be compared within or between
medical specialties.
Assessment of early signs of disability
becomes increasingly important in the con-
text of current research on neuroprotection
and symptomatic treatment in PD.18 The
objective of this study was therefore to ex-
amine the clinimetric properties of the
ALDS item bank in patients with newly di-
agnosed PD in terms of internal consis-
tency reliability, validity, and the presence
of a ceiling effect. In line with this objective
and in agreement with our previous stud-
ies,19,20 we hypothesized that the ALDS
1) has an internal consistency reliability ex-
ceeding the 0.80 coefficient alpha value,
2) is moderately correlated with other dis-
ability measures and lower correlated with
instruments that measure other aspects of
health, 3) is able to distinguish between
clinical different groups, and 4) shows less
of a ceiling effect compared to the often
used S&E index.
METHODS Subjects. The study sample comprised 133
consecutive patients with newly diagnosed PD, recruited
from the neurology outpatient clinics of six general hospitals
in the Netherlands (Meander Medical Center Amersfoort,
Medical Center Alkmaar, Academic Medical Center Am-
sterdam, St. Lucas-Andreas Hospital Amsterdam, Sloter-
vaart Hospital Amsterdam, and OLVG Amsterdam)
between July 2002 and March 2005. ALDS data from 132
patients was available and used for analysis. The clinical di-
agnosis of PD was based on internationally accepted diag-
nostic criteria.21 Patients were excluded if they were aged 85
years or older, had insufficient proficiency in the Dutch lan-
guage, or had a somatic illness and a life expectancy of less
than a year. The patients in this study were participants in a
longitudinal research project investigating the course of
functional status and its determinants in PD. The data pre-
sented here were obtained at the baseline assessment. Writ-
ten informed consent was obtained from all subjects after the
nature of the study had been fully explained. The study was
approved by the local ethics committees of the participating
hospitals.
Procedure. Neurologic examination of all patients was
performed to confirm the diagnosis of PD. Information
about demographic characteristics, duration of the disease
(time between the appearance of the first symptom of PD as
reported by the patient and the moment of assessment), ini-
tial symptoms and side of onset of disease, medication, and
response to levodopa (L-dopa) therapy was obtained with a
semi-structured interview. As this was a cohort of newly di-
agnosed patients without “on”–“off” response fluctuation it
was not necessary to perform a standardized “on”–“off”
scoring.
The severity of extrapyramidal symptoms was rated us-
ing the motor examination part of the UPDRS (UPDRS-
ME).4 The stage of disease was determined with the Hoehn
and Yahr staging scale (H&Y).22 Functional status (disability
and quality of life) was evaluated using the S&E,9 the Medi-
cal Outcome Study 36-Item Short-Form General Health Sur-
vey (SF-36),23 the PD Quality of Life Questionnaire
(PDQL),24 and the ALDS.
Motor impairment assessment. The UPDRS consists of
four components: 1) mentation, behavior, and mood; 2) ac-
tivities of daily living; 3) motor examination; 4) complica-
tions of therapy.25 The UPDRS-ME quantifies type, number,
and severity of extrapyramidal signs. For each sign a five-
step severity gradation is used, with zero representing ab-
sence and four representing the maximum severity of that
sign. The total number of items is 27 with total scores rang-
ing from 0 to 108. The H&Y is the standard disease-staging
index for PD and consists of five levels: 1) unilateral symp-
toms only; 2) bilateral symptoms, without balance impair-
ment; 3) bilateral symptoms with definite impairment of
postural reflexes; 4) severe disability, but still able to walk or
stand unassisted; 5) wheelchair-bound or bedridden.
Disability and quality of life. The S&E was specifically
designed for patients with PD and reflects the patient’s abil-
ity to perform daily activities in terms of speed and indepen-
dence. ADL ability is measured on an 11-point scale ranging
from 0% (vegetative function) to 100% (complete indepen-
dence). The SF-36 consists of eight health concepts: physical
functioning (SF-36 PF), role-physical, bodily pain, general
health, vitality, social functioning, role-emotional, and men-
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tal health. The eight scales define two distinct components:
the physical component score (SF-36 PCS) (SF-36 PF, role
limitations caused by physical problems, bodily pain, gen-
eral health) and the mental component score (SF-36 MCS)
(vitality, social functioning, role limitations caused by emo-
tional problems and mental health). Each dimension is
scored from 0 to 100. A high score suggests good health. The
PDQL consists of total score and four subsections: parkinso-
nian symptoms (14 items), systemic symptoms (7 items), so-
cial function (7 items), and emotional function (PDQL EF)
(9 items: score range 9 to 45). The items are scored on a
five-point Likert scale (score range 37 to 185). Higher scores
indicate a better quality of life.
We consider the S&E and the SF-36 PF as disability mea-
sures, the SF-36 PCS as a generic “perceived” functional sta-
tus measure, and the SF-36 MCS and the PDQL EF as
instruments focusing on the psychological aspects of quality
of life.
AMC linear disability item bank. The ALDS item bank
was developed to quantify functional status in terms of the
ability to perform ADL using an IRT framework.16 The
items were obtained from a systematic review of generic and
disease-specific functional health instruments.8 Both the item
difficulty and the patient’s ability are arranged on a single
hierarchical linear scale. The current version of the item
bank consists of 77 items, ranging from relatively easy to
difficult19 (see appendix E-1 on theNeurology® Web site at
www.neurology.org for further details). Researchers can use
their clinical judgment to select items from the item bank
that are applicable to the population they are investigating.
This flexible approach results in a range of individual con-
structed scales specifically targeted to the patient’s ability
level. Hence, these tailored scales may be quite different
from even patient to patient, but all assess the construct of
interest because the items are all selected from an item bank
which has previously been calibrated.13 Consequently, items
which have a similar difficulty grade are interchangeable and
can be used to assemble scales with items that may be of
interest for different patient groups. In this way the item
bank can be used to assess patients with a wide range of
conditions and levels of functional status, without putting
undue strain on them. The methodology16 (appendix E-2),
the psychometrics of the ALDS in terms of dealing with miss-
ing data,20 differences between item measurement character-
istics of the item bank in relation to age and sex,26 and the
metric properties of ALDS items in mixed types of patient
groups,19 as well as the statistical power to detect given effect
sizes in clinical trials using IRT outcome scales,27 have been
examined in depth.
In this study, depending on his or her ability level, each
patient was assessed with a number of the 77 items in the
current version of the item bank (ranging from 7 to 43 items
per patient; 35 items on average in the present study) to esti-
mate his or her functional status. Beforehand different item
sets were composed by two of the authors (N.W., R.d.H.). If
only limited information was available on the ability status
of the patient a selection of items covering the whole range of
the item bank was presented. Mildly disabled patients were
presented with more difficult items because those were likely
to provide more information. On the other hand, more eas-
ier items lower on the scale were presented to more disabled
patients. Some patients were assessed with only seven items
because there were no remaining items that should have
given additional information to the estimation of the pa-
tient’s disability level (patients at the ceiling or the floor of
the distribution). The items were administered by trained
nurses and had two response options: “I can carry out the
activity” and “I cannot carry out the activity.” Participants
were asked to indicate whether they could perform the activ-
ities now in the same way that they would at home or in the
location where they were residing. If an activity had never
before been performed by a patient (e.g., “travel by local bus
or tram”), or the patients’ response was “I do not know,”
“not applicable” was recorded.
The original units of the ALDS scale are (logistic) regres-
sion coefficients, expressed in logits (appendix E-1). To
make the results easier to interpret, the logit scores are lin-
early transformed (the interval level stays preserved) into
values between 0 (dead) and 100. The value 1 represents the
lowest level and the value 100 the highest level of functional
status possible. (The complete item bank, psychometric
properties of the individual items, and scoring rules are
available upon request.)
Clinimetric evaluation. The clinimetric properties of the
ALDS were studied in terms of internal consistency reliabil-
ity, validity, and the presence of a ceiling effect. Internal con-
sistency refers to the statistical coherence of the scale items.
One measure of internal consistency is the Cronbach  coef-
ficient,28 based on the (weighted) average correlation of
items within a scale. Internal consistency is considered to be
good if   0.80.29 We also calculated item-total correla-
tions, which represent the correlation of a single item with
the sum of all other items. Correlations0.20 or more were
considered to be sufficient.30
With regard to the validity of the ALDS we focused on
both its construct validity and clinical validity (also known
as known-groups validity). Construct validity was assessed
by measuring the extent to which the ALDS correlates with
measures (S&E, SF-36 PF, SF-36 PCS) that address the same
concept and measures (H&Y, UPDRS-ME, SF-36 MCS,
PDQL EF) that address conceptually different aspects of
health. We assumed that in order for the ALDS to be valid,
the ALDS scores had to show a decreasing pattern of associ-
ations, with higher correlations with the other disability-
oriented scale scores, intermediate correlations with
neurologic impairments, and lower correlations with the
psychological aspects of quality of life. A scale demonstrates
clinical validity if it discriminates between groups of patients
with known differences in clinical status, in this case disease
severity based on the H&Y, severity of extrapyramidal
symptoms based on the UPDRS-ME, and the presence of
postural instability (item 30). Absence of posture instability
was defined as score 0 (normal); a score 1 (1  retropul-
sion; 2  absence of postural response) was defined as pos-
tural instability. With regard to a ceiling effect, the
percentage of patients that reached a maximum score on the
S&E and ALDS was presented.
Statistical analysis. Patient characteristics, outcome
scores, and ceiling effects were analyzed using descriptive
statistics. Scores on the ALDS instrument were calculated
using previously published item properties19 and algorithms
implemented in BILOG-MG31 and SPSS. ALDS items that a
patient had not responded to or had answered not applicable
were treated as if they had not been offered to that patient.20
Values of Cronbach  were obtained using an IRT method
that allows for missing item responses28,32 implemented in
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TESTFACT.31 Item-total correlations, as well as the associa-
tions between the ALDS scores and the other measures, were
expressed in Pearson (r) or Spearman correlation coefficients
(rs), when appropriate.
Normality tests showed a normal distribution of the
ALDS. Therefore, the data were analyzed using parametric
statistics. Differences between mean ALDS scores (with 95%
CI) were analyzed using an independent t test or one-way
analysis of variance (ANOVA), including post hoc Tukey
HSD tests (significance level 0.05). The concerning effect size
for ANOVAmain effect result was expressed in Cohen f and
for the independent t test in Cohen d. The original ALDS
logits were used in all analyses but for the sake of clarity only
the linearly transformed ALDS scores (0 to 100) are
presented.
RESULTS The study included 132 patients with
newly diagnosed PD, 74 (56%) of whom were
men. The mean age at onset of symptoms was 65
(SD  10.4); the patients’ mean age at examina-
tion was 66.7 (SD  10.4 years). Mean disease
duration at examination was 19.9 (SD  11.2)
months. Eighty-four (64%) patients were taking
L-dopa. Further clinical characteristics of the sam-
ple are shown in table 1.
The internal consistency reliability of the
ALDS was good (Cronbach   0.95). Of the 77
items, 55 items showed item-total correlations
with values ranging from r 0.20 to r 0.68, all
exceeding the 0.20 standard. Sixteen items had
no score variation; consequently, no correlations
could be calculated (e.g., “take off a T-shirt”),
whereas five items showed item-total correlations
0.20 (range0.03 to 0.19).
Table 2 presents the descriptive statistics of the
instruments and the correlation coefficients be-
tween the ALDS and the other scales. The highest
associations occurred between the ALDS and
other disability measures: S&E (rs  0.50), SF-36
PF (r 0.63), and SF-36 PCS (r 0.55). Addition-
ally, the ALDS showed a decreasing pattern of as-
sociations between the scales measuring
neurologic impairments (H&Y; r  0.36, UP-
DRS-ME; r  0.37) and mental health (SF-36
MCS; r0.01, PDQL EF; r 0.23).
With regard to the clinical (known-group) va-
lidity (table 3), ALDS scores registered an associ-
ation between the severity of PD as determined by
H&Y classification and impaired disability status
(one-way ANOVA; F 12.06, p 0.0001; Cohen
Table 1 Clinical characteristics of the 132 patients with newly diagnosed PD
Clinical variables Total (n 132)
Gender (men) (%) 74 (56%)
Age at onset of symptoms, mean y (SD; range) 65 (10.4; 30.9–83.5)
Age at diagnosis of PD, mean y (SD; range) 66.3 (10.4; 32–84.6)
Age at examination, mean y (SD; range) 66.7 (10.4; 32.4–84.9)
Duration of symptoms at examination, mean mo (SD; range) 19.9 (11.2; 4.7–83.9)
Symptoms at start of the disease (%)
Tremor 60 (45)
Bradykinesia/rigidity 61 (46)
Tremor/bradykinesia/rigidity 11 (8)
Side of symptom onset*
Unilateral (RL) 98 (4850)
Two sides asymmetric 13
Two sides symmetric 19
Receiving dopaminergic therapy (%) 84 (64)
LED when receiving dopaminergic therapy, mean
(SD, range) 152 (148; 0–600)
Sum score UPDRS-ME, mean (SD, range) 17.5 (8.2; 5–40)
H&Y score (%)
1 47 (36)
1.5 7 (5)
2 40 (30)
2.5 22 (17)
3 16 (12)
4 0
5 0
*Side of symptom onset is missing for two patients.
PD Parkinson disease; LED levodopa equivalent dose; UPDRS-MEUnified Parkinson’s
Disease Rating Scale motor examination; H&Y Hoehn and Yahr.
Table 2 Descriptive statistics of the instruments and correlations between the ALDS and other Parkinson
disease measures
S&E
(n 132)
SF-36 PF
(n 130)
SF-36 PCS
(n 122)
H&Y
(n 132)
UPDRS-ME
(n 132)
SF-36MCS
(n 122)
PDQL EF
(n 123)
90 (60–100) 66.1 (24.1) 43.7 (10.1) 2 (1–3) 17.5 (8.2) 44.5 (12) 35.9 (5.9)
ALDS 82.7 ( 8.67) 0.50 0.63 0.55 0.36* 0.37* 0.01† 0.23
Score values are mean (SD), except for the S&E and the H&Y, which are presented in median and range; correlation values
are Pearson correlation coefficient and calculated with the ALDS logits, with the exception of the association between the
S&E and the H&Y, which are expressed in Spearman correlation coefficient.
*Since higher H&Y and UPDRS-ME scores indicate more neurologic deficits, signs of the coefficients are the opposite of
those of other scales.
†All correlation coefficients are significant at the 0.01 level, except for the correlation with SF-36 MCS (p 0.94).
ALDSAMCLinear Disability Score; S&ESchwab and England scale; SFShort Form; H&YHoehn and Yahr; UPDRS
Unified PD Rating Scale; PDQL PD Quality of Life Questionnaire.
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f  0.60). Patients with H&Y stage 3 had lower
ALDS scores compared to H&Y stage 2 (Tukey
HSD; p 0.0001) and H&Y stage 1 (Tukey HSD;
p 0.0001). However, the ALDS scores were not
different between H&Y stage 1 and stage 2 (Tukey
HSD; p  0.36). The score distributions of the
ALDS reflect that patients with more severe extra-
pyramidal symptoms (UPDRS-ME  15.5) were
more disabled (independent t test; t  3.53, p 
0.001; Cohen d 0.62) than patientswith less severe
extrapyramidal symptoms (UPDSR-ME  15.5).
Additionally, the ALDS showed an association be-
tween postural (in)stability and disability level (in-
dependent t test; t  4.30, p  0.0001; Cohen d 
0.65).
Six patients (5%) had a maximum ALDS
score; the percentage of patients scoring at the
ceiling of the S&E (score  100%) was substan-
tially higher (19%). The figure presents the mea-
surement range of the ALDS items in case of a
maximum S&E (100% score). These less disabled
patients could still be differentiated with seven
ALDS items, ranging from walking in the woods
to heavy household tasks.
DISCUSSION In this study we expanded the psy-
chometric evaluations of the ALDS8,16,17,19,20,26,27 to
patients with early PD. We showed the ALDS has
promising clinimetric properties in terms of inter-
nal consistency reliability, construct and clinical
validity, and absence of ceiling effects.
The internal consistency of the ALDS was high
(Cronbach   0.95). Though Cronbach alpha is
a well-established measure of internal consis-
tency, it is dependent also on the number of items
in the scale. In this study 35 items were assessed at
average. Therefore, the high alpha must be inter-
preted with certain caution. Nevertheless, 70% of
the ALDS items exceeded the item-total correla-
tion standard of 0.20, reflecting good internal
consistency as well. Six percent of the items were
below the required level. No item-total correla-
tions could be calculated in 20% of the items.
These were 16 items mainly at the lower end of
the scale. All patients were able to perform those
items and indicate the high ability level of the pa-
tients with PD studied. This does not mean that
they should be omitted from the ALDS. First,
these items have psychometric qualities,19 and sec-
ond, an assessment of those items could provide
useful clinical information in more disabled pa-
tients with PD. However, we advise not to apply
those items in a newly diagnosed PD patient
group.
The correlations between the ALDS on the one
hand and the S&E and physical aspects of the
SF-36 on the other indicate that these scales
largely focus on the same construct, which is dis-
ability. The decreasing correlation between the
ALDS and measures of neurologic disturbances
and psychological well-being demonstrates the
ALDS is less focused on conceptually different as-
pects of health in terms of impairments or quality
of life.
Table 3 Score distributions of the ALDS between groups of patients with
known differences in clinical status: Clinical validity
No. ALDS p Value Effect size
H&Y 0.0001 0.60
Stage 1 (mild) 54 84.6 (6.2; 83.0–86.3)
Stage 2 (moderate) 62 83.1 (9.5; 80.7–85.4)
Stage 3 (severe) 16 75.2 (8.9; 70.5–79.6)
UPDRS-ME* 0.001 0.62
15.5 66 84.8 (8.2; 82.8–86.7)
15.5 66 80.7 (8.7; 78.6–82.8)
Posture (item 30)† 0.0001 0.65
Score 0 92 84.6 (5.2; 83.6–85.7)
Score1 40 78.3 (12.6; 74.9–81.6)
Score distributions are presented in mean (SD; 95% CI); differences in mean logit scores
are calculated using one-way analysis of variance (ANOVA) (H&Y), and an independent t test
(UPDRS-ME, posture item 30). Effect size for ANOVA was expressed in Cohen f, for the
independent t test in Cohen d.
*UPDRS-ME was dichotomized on base of the median value of the scores.
†Score range of item 30 was 0 to 2; 0  normal; 1  retropulsion; 2  absence of postural
response.
ALDS  AMC Linear Disability Score; H&Y  Hoehn and Yahr; UPDRS  Unified PD Rating
Scale.
Figure Measurement range of AMC Linear
Disability Score items in patients with
a maximum Schwab and England
scale score 100% (n 25)
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Our findings that the ALDS scores differenti-
ate between moderate and severe disease as well
as more or less extrapyramidal symptoms indi-
cate that the ALDS is sufficiently sensitive to dis-
tinguish different patient groups. However,
between mild and moderate patients, we did not
find differences in ALDS scores. This can be due
to the reason that impairments in early PD (H&Y
stage 1 and 2) lead to no or subtle differences in
disability. Moreover, patients with postural insta-
bility showed significantly lower ALDS scores
compared to patients without postural instability.
By administering the ALDS only those items
relevant to a person’s disability status is used,
thereby reducing patient burden in time and ef-
fort. The ALDS will form a good foundation for a
computerized adaptive testing procedure, allow-
ing for shorter questionnaires where the difficulty
level is automatically adapted per question de-
pending on the individual patient’s ability to per-
form the questioned activity.33 Obviously, this is
an initial study on the use of the ALDS in PD
which provides the basis for further testing.
A limitation of our study is that we did not
compare the ALDS with the currently most
widely used UPDRS-ADL score.34 The patients in
this study were participants in a longitudinal re-
search project investigating the course of func-
tional status and its determinants in PD.
Unfortunately, this study did not include the eval-
uation of functional status by this scale.
In our inception cohort of newly diagnosed pa-
tients, severe disease stages (H&Y 4 and 5) have
not been represented. We showed in our study
that the ALDS, compared to the S&E, had a
smaller amount of ceiling effect. For example, pa-
tients with an S&E score of 100% can still be dif-
ferentiated by ALDS items. However, potential
floor effects should be investigated in future
research.
Investigating the clinimetric properties of a
scale is an ongoing process. The present study is a
first step in the validation process of the ALDS in
patients with PD. Further studies are needed to
investigate whether the ALDS provides consistent
scores over time and between observers (test-
retest, inter/intrarater reliability), to compare the
ALDS with the UPDRS-ADL, to follow patients
who reflect the whole severity spectrum of the
disease, and to examine the responsiveness of the
ALDS to measure changes in disability over time.
Good responsiveness is likely due to the scale’s
linearity, its absence of ceiling effects, and its flex-
ibility to choose among a wide range of patient
tailored items.
The ALDS is a new, generic, non-disease-
specific scale consisting of 77 ADL items. Our
data show that the ALDS has good internal con-
sistency reliability, did not demonstrate a ceiling
effect, and indicates good construct and clinical
validity in patients with newly diagnosed PD.
Currently, we are extending the psychometric
properties of the item bank to a variety of other
neurologic diseases and by calibrating more items
especially at the floor and the ceiling of the item
bank.
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2008 AAN Winter Conference in Miami Presents
New Courses, Dystonia Workshop
If you missed the 2007 AAN Annual Meeting and the 2007 Fall Conference, and need to earn
CME credits, reserve the weekend of January 18 through 20, 2008, for the AAN Winter
Conference in Miami. Neurologists, nurses, and practice managers can enjoy learning from
leading experts in a small-group setting. In addition, new practice management courses will
be structured in basic and advanced segments. A Dystonia Workshop also will be offered on
January 18. Early registration deadline is December 28, 2007. Visit www.aan.com/winter08
for more information about the programs and early registration discount.
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